State Street Corp Decreases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

State Street Corp decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,238,224 shares of the biotechnology company's stock after selling 56,009 shares during the period. State Street Corp owned 5.01% of United Therapeutics worth $802,068,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Quantinno Capital Management LP raised its stake in United Therapeutics by 32.7% during the third quarter. Quantinno Capital Management LP now owns 1,308 shares of the biotechnology company's stock valued at $469,000 after buying an additional 322 shares during the last quarter. Redwood Investment Management LLC raised its position in shares of United Therapeutics by 4.0% in the 3rd quarter. Redwood Investment Management LLC now owns 4,522 shares of the biotechnology company's stock worth $1,621,000 after purchasing an additional 174 shares during the last quarter. Retirement Investment Advisors Inc. bought a new position in United Therapeutics in the 3rd quarter worth about $215,000. Janus Henderson Group PLC raised its holdings in United Therapeutics by 12.3% in the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock worth $164,978,000 after buying an additional 50,409 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in shares of United Therapeutics by 6.7% during the third quarter. HighTower Advisors LLC now owns 18,050 shares of the biotechnology company's stock valued at $6,493,000 after buying an additional 1,135 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, Director Christopher Causey sold 510 shares of the firm's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the transaction, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This trade represents a 12.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO James Edgemond sold 7,802 shares of United Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the completion of the sale, the chief financial officer now owns 3,210 shares of the company's stock, valued at $1,108,766.10. The trade was a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 127,142 shares of company stock worth $47,460,419 over the last 90 days. Company insiders own 11.90% of the company's stock.

Analyst Ratings Changes

UTHR has been the subject of a number of recent analyst reports. Jefferies Financial Group boosted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Wells Fargo & Company upped their price target on United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a report on Tuesday, August 20th. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. Finally, LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Stock Down 1.3 %

NASDAQ:UTHR traded down $4.70 during trading hours on Friday, hitting $369.67. 199,272 shares of the stock traded hands, compared to its average volume of 303,476. The stock has a 50 day moving average price of $369.14 and a 200 day moving average price of $339.06. The company has a market cap of $16.51 billion, a price-to-earnings ratio of 16.23, a price-to-earnings-growth ratio of 1.07 and a beta of 0.54. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.38 earnings per share. Equities analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.